LTS Leaderboard

Main Menu

  • Home
  • Silver News
  • Nationalization
  • Liquidity crisis
  • Stock Options
  • Saving Investment

LTS Leaderboard

Header Banner

LTS Leaderboard

  • Home
  • Silver News
  • Nationalization
  • Liquidity crisis
  • Stock Options
  • Saving Investment
Stock Options
Home›Stock Options›FDA rejection halts Teva Pharmaceutical Stock rally

FDA rejection halts Teva Pharmaceutical Stock rally

By Mary Jenkins
April 20, 2022
5
0

The FDA just rejected Teva Pharmaceuticals’ marketing application for its schizophrenia treatment

The actions of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are down 3.3% to $9.84 this morning following news that the U.S. Food and Drug Administration (FDA) has sent a letter rejecting the company’s marketing application for its treatment of schizophrenia. Teva said it is currently reviewing its next steps and plans to work closely with the FDA as it considers their options. The treatment was created in partnership with French pharmaceutical developer MedinCell (MEDCL), whose work is also making headlines.

Despite today’s decline, however, TEVA is still a relative outperformer on the charts. The stock has managed to add around 27% in 2022, although today’s decline will take it even lower from recent pressure at its year-over-year breakeven. The stock recently broke a former rejection level at the 320-day moving average after an opioid settlement helped it climb the charts in mid-March, and that trendline could still serve as a floor. in the future.

Analysts remained bearish on Teva stock, even after Bernstein has changed his tone late last month. Of the 12 covers, 10 call it a “hold” or worse, versus two “strong buy” ratings. Additionally, the 12-month consensus price target of $10.81 is a slim 6.2% premium to last night’s close.

Futures options traders have been a lot heavier than usual lately. This is Schaeffer’s TEVA put/call open interest ratio (SOIR) of 0.87, which is above 96% of last year’s readings.

Related posts:

  1. Govt Order on U.S. Provide Chains – Technique
  2. These choices may also help you generate long run passive revenue
  3. Insider shopping for: Fastenal Firm (NASDAQ: FAST) unbiased director simply purchased 18% extra shares
  4. Did you take part in considered one of Deswell Industries (NASDAQ: DSWL) incredible 175% returns?

Categories

  • Liquidity crisis
  • Nationalization
  • Saving Investment
  • Silver News
  • Stock Options
  • TERMS AND CONDITIONS
  • PRIVACY AND POLICY